Resistance to EGFR-targeted therapy: a family affair

Gregory Vlacich; Robert J Coffey

doi:10.1016/j.ccr.2011.10.006

Resistance to EGFR-targeted therapy: a family affair

Cancer Cell. 2011 Oct 18;20(4):423-5. doi: 10.1016/j.ccr.2011.10.006.

Authors

Gregory Vlacich¹, Robert J Coffey

Affiliation

¹ Department of Radiation Oncology, Vanderbilt University, Nashville, TN 37232-2279, USA.

Abstract

The EGFR-directed antibody cetuximab has proven, albeit modest, clinical benefit as monotherapy in head and neck and colorectal cancers. In a recent study, Yonesaka et al. uncovered a new mechanism of cetuximab resistance mediated by increased ERBB2 signaling via amplification of ERBB2 or increased levels of the ERBB3/ERBB4 ligand heregulin.

Publication types

Comment

Abstract

Publication types

Grants and funding